drugset / Trial / NCT00836069
Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a randomized, double-blind, parallel-group, multi-site, Phase 3, placebo controlled fixed-dose study of PD 0332334 and paroxetine in 528 outpatients with generalized anxiety disorder. Subjects will be randomized to the following treatments (132 subjects per treatment group): PD 0332334 225 mg twice a day (450 mg/day), PD 0332334 300 mg twice a day (600 mg/day), placebo once a day in the morning or paroxetine 20 mg once a day in the morning (20 mg/day).
Timeline
- Start
- 2008-10
- Primary completion
- 2009-02
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMAGABALIN | Other / unclassified | 225 mg | Oral |
| Subject | IMAGABALIN | Other / unclassified | 300 mg | Oral |
| Comparator | Paroxetine | Small molecule | 20 mg | Oral |